We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Topotecan and Cisplatin Versus Etoposide and Carboplatin in 1st Line Treatment of Patients With Small Cell Lung Cancer and Extensive Disease (SCLC-ED)

This study has been terminated.
(Slow accrual)
Sponsor:
ClinicalTrials.gov Identifier:
NCT00812266
First Posted: December 22, 2008
Last Update Posted: January 26, 2016
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Seppo W. Langer, Danish Oncological Lung Cancer Group
December 19, 2008
December 22, 2008
January 26, 2016
January 2006
December 2013   (Final data collection date for primary outcome measure)
2 years survival [ Time Frame: 2 years ]
Same as current
Complete list of historical versions of study NCT00812266 on ClinicalTrials.gov Archive Site
Response rates [ Time Frame: 2 years ]
Same as current
Not Provided
Not Provided
 
Topotecan and Cisplatin Versus Etoposide and Carboplatin in 1st Line Treatment of Patients With Small Cell Lung Cancer and Extensive Disease (SCLC-ED)
Randomized Phase III Trial of Topotecan and Cisplatin Versus Etoposide and Carboplatin in the Treatment of Patients With Previously Untreated Small Cell Lung Cancer and Extensive Disease
Randomised trial comparing standard chemotherapy with carboplatin and etoposide with a combination of topotecan and cisplatin in patients with inoperable lung cancer of small cell type.
Fase III, multicenter randomised trial comparing up to six cycles of carboplatin and etoposide with up to six cycles of topotecan and cisplatin in patients with extensive stage small cell lung cancer and PS 0-3
Interventional
Phase 3
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
  • Extensive Disease
  • First-Line
  • Small Cell Lung Cancer
  • Drug: topotecan + cisplatin
    topotecan IV 2 mg/sqm d1-3 + cisplatin IV 50 mg/sqm d3 q3W
  • Drug: Etoposide + carboplatin
    Etoposide 120 mg/sqm IV d 1-3 + carboplatin AUC 5 d1 q3W
  • Experimental: A
    Topotecan + cisplatin
    Intervention: Drug: topotecan + cisplatin
  • Active Comparator: B
    Etoposide + carboplatin
    Intervention: Drug: Etoposide + carboplatin
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
281
January 2015
December 2013   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Histologically confirmed SCLC
  • Extensive stage
  • No prior chemotherapy
  • WHO PS 0-3
  • Adequate organ function (liver, kidney)
  • Adequate hematology (bone marrow)
  • Informed consent

Exclusion Criteria:

  • PS 4
  • Inadequate organ function
  • Uncontrolled infection
  • Concomitant major medical contraindications
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Denmark
 
 
NCT00812266
DOLG7
DOLG7 ( Other Identifier: Danish Oncological Lung Cancer Group Number )
No
Not Provided
Not Provided
Seppo W. Langer, Danish Oncological Lung Cancer Group
Danish Oncological Lung Cancer Group
Not Provided
Principal Investigator: Seppo W Langer, MD PhD Dept. of Oncology, Rigshospitalet, Copenhagen
Danish Oncological Lung Cancer Group
January 2016

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP